Bridging the translational gap: collaborative drug development and dispelling the stigma of commercialization

Helen Yu

Bridging the translational gap: collaborative drug development and dispelling the stigma of commercialization

CIIR - Center for Informations- og innovationsret

8 Citationer (Scopus)

Abstract

The current drug discovery and development process is stalling the translation of basic science into lifesaving products. Known as the 'Valley of Death', the traditional technology transfer model fails to bridge the gap between early-stage discoveries and preclinical research to advance innovations beyond the discovery phase. In addition, the stigma associated with 'commercialization' detracts from the importance of efficient translation of basic research. Here, I introduce a drug discovery model whereby the respective expertise of academia and industry are brought together to take promising discoveries through to proof of concept as a way to derisk the drug discovery and development process. Known as the 'integrated drug discovery model', I examine here the extent to which existing legal frameworks support this model.

Originalsprog	Engelsk
Tidsskrift	Drug Discovery Today
Vol/bind	21
Udgave nummer	2
Sider (fra-til)	299-305
Antal sider	7
ISSN	1359-6446
Status	Udgivet - 2016

Citationsformater

@article{7262d9294a134867a812d380b3995b92,

title = "Bridging the translational gap: collaborative drug development and dispelling the stigma of commercialization",

abstract = "The current drug discovery and development process is stalling the translation of basic science into lifesaving products. Known as the 'Valley of Death', the traditional technology transfer model fails to bridge the gap between early-stage discoveries and preclinical research to advance innovations beyond the discovery phase. In addition, the stigma associated with 'commercialization' detracts from the importance of efficient translation of basic research. Here, I introduce a drug discovery model whereby the respective expertise of academia and industry are brought together to take promising discoveries through to proof of concept as a way to derisk the drug discovery and development process. Known as the 'integrated drug discovery model', I examine here the extent to which existing legal frameworks support this model.",

author = "Helen Yu",

year = "2016",

language = "English",

volume = "21",

pages = "299--305",

journal = "Drug Discovery Today",

issn = "1359-6446",

publisher = "Elsevier Ltd. * Trends Journals",

number = "2",

}

TY - JOUR

T1 - Bridging the translational gap: collaborative drug development and dispelling the stigma of commercialization

AU - Yu, Helen

PY - 2016

Y1 - 2016

N2 - The current drug discovery and development process is stalling the translation of basic science into lifesaving products. Known as the 'Valley of Death', the traditional technology transfer model fails to bridge the gap between early-stage discoveries and preclinical research to advance innovations beyond the discovery phase. In addition, the stigma associated with 'commercialization' detracts from the importance of efficient translation of basic research. Here, I introduce a drug discovery model whereby the respective expertise of academia and industry are brought together to take promising discoveries through to proof of concept as a way to derisk the drug discovery and development process. Known as the 'integrated drug discovery model', I examine here the extent to which existing legal frameworks support this model.

AB - The current drug discovery and development process is stalling the translation of basic science into lifesaving products. Known as the 'Valley of Death', the traditional technology transfer model fails to bridge the gap between early-stage discoveries and preclinical research to advance innovations beyond the discovery phase. In addition, the stigma associated with 'commercialization' detracts from the importance of efficient translation of basic research. Here, I introduce a drug discovery model whereby the respective expertise of academia and industry are brought together to take promising discoveries through to proof of concept as a way to derisk the drug discovery and development process. Known as the 'integrated drug discovery model', I examine here the extent to which existing legal frameworks support this model.

M3 - Journal article

SN - 1359-6446

VL - 21

SP - 299

EP - 305

JO - Drug Discovery Today

JF - Drug Discovery Today

IS - 2

ER -

Bridging the translational gap: collaborative drug development and dispelling the stigma of commercialization

Abstract

Fingeraftryk

Citationsformater